Company Overview: Asterias Biotherapeutics

Industry News

17 Jul

Asterias Biotherapeutics Completes Enrollment and Dosing of SCiStar Study’s AIS-A 20 Million Cell Cohort

Twenty patients have been enrolled in SCiStar study 20 million cell dose escalation cohort to inform future trial design Dosing fifth patient in this cohort triggers $1.5 million grant payment FREMONT, Calif., July 17, 2017 /PRNewswire/ — Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company pioneering the field of regenerative medicine, today announced...

Read more

12 Jul

Asterias Biotherapeutics Completes Enrollment and Dosing of SCiStar Study’s AIS-B 10 Million Cell Cohort

First enrolled cohort comprised of patients with motor complete, sensory incomplete paralysis FREMONT, Calif., July 12, 2017 /PRNewswire/ — Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company pioneering the field of regenerative medicine, today announced completion of enrollment and dosing of the AIS-B 10 million cell cohort in the company’s ongoing...

Read more

10 Jul

Asterias Biotherapeutics Receives FDA Clearance to Enroll C-4 Patients in SCiStar Study

Ability to enroll patients with second most common cervical spinal cord injury broadens eligible population for SCiStar study and future trials FREMONT, Calif., July 10, 2017 /PRNewswire/ — Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company pioneering the field of regenerative medicine, today announced that the U.S. Food and Drug Administration...

Read more

13 Jun

Patients with Complete Paralysis Show Additional Recovery of Arm, Hand and Finger Function at 9-months After Treatment with Asterias’ AST-OPC1

FREMONT, Calif., June 13, 2017 /PRNewswire/ — Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company pioneering the field of regenerative medicine, today announced that new 9-month follow-up data from the AIS-A 10 million cell cohort in the company’s ongoing SCiStar Phase 1/2a clinical trial shows three of six (50%)...

Read more

11 May

New MRI Data from Asterias’ Ongoing SCiStar Clinical Study Indicates AST-OPC1 Cells Prevent Formation of Damaging Lesion Cavities in Patients Suffering Severe Spinal Cord Injury

FREMONT, Calif., May 11, 2017 /PRNewswire/ — Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company pioneering the field of regenerative medicine, today announced new positive serial magnetic resonance imaging (MRI) data from its ongoing AST-OPC1 SCiStar Phase 1/2a clinical trial in patients with severe spinal cord injury, including: For...

Read more

4 May

Asterias Biotherapeutics to Report First Quarter Results on May 11, 2017

FREMONT, Calif., May 4, 2017 /PRNewswire/ — Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, today announced that it will release first quarter 2017 financial and operational results on Thursday, May 11, 2017 after the close of the U.S. financial markets....

Read more

3 May

Presidential Symposium at the American Society of Gene and Cell Therapy (ASGCT) 20th Annual Meeting Will Feature Presentation on Asterias’ AST-OPC1 for Spinal Cord Injury

FREMONT, Calif., May 3, 2017 /PRNewswire/ — Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company pioneering the field of regenerative medicine, today announced that data from its AST-OPC1 clinical program for severe cervical spinal cord injury will be presented during the Presidential Symposium at the American Society of Gene...

Read more

26 Apr

Asterias Announces Publication of Positive Phase 2 Data on AST-VAC1 for the Treatment of Acute Myeloid Leukemia (AML) in ‘Cancer’

FREMONT, Calif., April 26, 2017 /PRNewswire/ — Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, today announced that the results from its completed Phase 2 clinical trial of AST-VAC1 are now available online in Cancer,  a leading peer-reviewed journal of the...

Read more

28 Mar

Asterias Biotherapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Recent Development Progress

FREMONT, Calif., March 28, 2017 /PRNewswire/ — Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company pioneering the field of regenerative medicine, today reported financial and operational results for the fourth quarter and year ended December 31, 2016 as well as  recent corporate progress. “Asterias has achieved substantial progress over...

Read more

21 Mar

Update on Full Six-Patient Cohort Confirms Patients with Complete Paralysis Can Experience Meaningful Recovery of Function by Six Months Following AST-OPC1 Treatment

FREMONT, Calif., March 21, 2017 /PRNewswire/ — Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company pioneering the field of regenerative medicine, reported that including the sixth and final patient in the AIS-A 10 million cell cohort in the company’s ongoing SCiStar Phase 1/2a clinical trial has further confirmed...

Read more

Page 1 of 212

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address